Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15 Leukemia, Myeloid, Chronic-Phase 6 Neoplasm Metastasis 4 Neoplasms 3 Philadelphia Chromosome 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Leukemia 2 Synovitis, Pigmented Villonodular 1 Sarcoma 1 Recurrence 1 Peritoneal Neoplasms 1 Neoplasm, Residual 1 Melanoma 1 Leukemia, Myeloid 1 Hematologic Diseases 1 Giant Cell Tumor of Tendon Sheath 1 Genital Neoplasms, Female 1 Gastrointestinal Stromal Tumors 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Chordoma 1 Cholangiocarcinoma 1 Breast Neoplasms 1 Blast Crisis 1 Appendiceal Neoplasms 1 Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Nivolumab 4 Ipilimumab 3 Specimen Handling 2 Proton Therapy 2 Magnetic Resonance Spectroscopy 2 Cetuximab 2 tazemetostat 1 spartalizumab 1 pembrolizumab 1 nilotinib 1 atezolizumab 1 Zoledronic Acid 1 X-Rays 1 Tiragolumab 1 Surveys and Questionnaires 1 Radiotherapy 1 Radiosurgery 1 Phantoms, Imaging 1 Imatinib Mesylate 1 Fluorodeoxyglucose F18 1 Cyclophosphamide 1 CTLA-4 Antigen 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Chordoma × nilotinib × 1 year × Clear all

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Massachusetts General Hospital

Phase 1 Completed

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡